Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its US partner VBI Vaccines Inc. (OTCMKTS: VBIVQ) has commenced bankruptcy reorganization proceedings. Brii Bio has a history of licensing agreements with VBI, securing exclusive global rights to BRII-179 and Asia-Pacific rights to PreHevbri (excluding Japan) in deals signed in 2018, 2023, and 2024. The companies also collaborated on clinical supplies for studies related to BRII-179.
Looking ahead, Brii Bio and VBI plan to transition the manufacturing of BRII-179 to a third-party contract research organization. Brii Bio has indicated that the bankruptcy proceedings of VBI will minimally impact its operations and financial status, and the development of BRII-179 will proceed as planned.
BRII-179 (VBI-2601) is an innovative immunotherapy for hepatitis B virus (HBV) that utilizes recombinant proteins capable of expressing Pre-S1, Pre-S2, and S HBV surface antigens. It is designed to elicit a robust and broad B and T cell immune response. PreHevbri, known as the only HBV vaccine with three antigens, includes the hepatitis B surface antigens S, pre S1, and pre S2. The vaccine is currently commercially available in the United States, European Union, the United Kingdom, Canada, and Israel.- Flcube.com
